Bibliographies thématiques / MF59 adjuvant prepandemic vaccination

Sommaire

Articles de revues
Thèses

Littérature scientifique sur le sujet « MF59 adjuvant prepandemic vaccination »

Auteur : Grafiati

Publié le 9 mars 2023

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « MF59 adjuvant prepandemic vaccination ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "MF59 adjuvant prepandemic vaccination"

Fragapane, Elena, Roberto Gasparini, Francesco Schioppa, Franco Laghi-Pasini, Emanuele Montomoli, and Angelika Banzhoff. "A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly." Clinical and Vaccine Immunology 17, no. 11 (2010): 1817–19. http://dx.doi.org/10.1128/cvi.00461-09.

Texte intégral

Résumé :

ABSTRACT Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

Styles APA, Harvard, Vancouver, ISO, etc.

Bihari, Iván, Gyula Pánczél, Jozsef Kovacs, Jenny Beygo, and Elena Fragapane. "Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects." Clinical and Vaccine Immunology 19, no. 12 (2012): 1943–48. http://dx.doi.org/10.1128/cvi.00373-12.

Texte intégral

Résumé :

ABSTRACTPreparedness against an A/H5N1 influenza pandemic requires well-tolerated, effective vaccines which provide both vaccine strain-specific and heterologous, cross-clade protection. This study was conducted to assess the immunogenicity and safety profile of an MF59-adjuvanted, prepandemic influenza vaccine containing A/turkey/Turkey/01/2005 (H5N1) strain viral antigen. A total of 343 participants, 194 adults (18 to 60 years) and 149 elderly individuals (≥61 years), received two doses of the investigational vaccine given 3 weeks apart. Homologous and heterologous antibody responses were an

Styles APA, Harvard, Vancouver, ISO, etc.

Lopez, Pio, Yolanda Caicedo, Alexandra Sierra, Sandrine Tilman, Ralf Clemens, and Angelika Banzhoff. "Combined Administration of MF59-Adjuvanted A/H5N1 Prepandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses 1 Year after a One-Dose Priming Schedule." Clinical and Vaccine Immunology 20, no. 5 (2013): 753–58. http://dx.doi.org/10.1128/cvi.00626-12.

Texte intégral

Résumé :

ABSTRACTHaving previously demonstrated the feasibility of administering A/H5N1 and seasonal influenza vaccine antigens in an MF59-adjuvanted tetravalent formulation, we now report on long-term antibody persistence and responses to a booster dose of a combined seasonal-pandemic, tetravalent influenza vaccine in adults. The primary objective was the evaluation of responses to a booster dose of tetravalent influenza vaccine containing seasonal (A/H1N1, A/H3N2, and B) and avian (A/H5N1, clade 2) influenza virus strains administered to 265 healthy 18- to 40-year-old volunteers 1 year after priming

Styles APA, Harvard, Vancouver, ISO, etc.

Chen, Wei, Yongxia Liu, Jinhua Yin, et al. "Cloning, Expression, and Immunogenicity of Fimbrial-F17A Subunit Vaccine againstEscherichia coliIsolated from Bovine Mastitis." BioMed Research International 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/3248483.

Texte intégral

Résumé :

There is a need to identify and select new promising immunodominant antigens that have the ability to provide protective immunity againstE. colicausing bovine mastitis. Recently we showed thatf17awas found to be the most prevalent and crucial virulent factor among the pathogenicE. coliisolated from bovine mastitis. Here, in this report, the recombinant F17A based subunit vaccine adjuvant with MF59 was tested for immunogenicity againstE. coliin a murine model. The vaccinated mice did not show any abnormal behavioral changes and histopathological lesions after vaccination. The specific antibody

Styles APA, Harvard, Vancouver, ISO, etc.

Del Giudice, Giuseppe, Elena Fragapane, Roberto Bugarini, et al. "Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene." Clinical and Vaccine Immunology 13, no. 9 (2006): 1010–13. http://dx.doi.org/10.1128/cvi.00191-06.

Texte intégral

Résumé :

ABSTRACT Squalene is a naturally occurring oil which has been used in the development of vaccine adjuvants, such as the oil-in-water emulsion MF59. In past years, by use of noncontrolled and nonvalidated assays, a claim was made that antisqualene antibodies were detectable in the sera of individuals with the so-called Gulf War syndrome. Using a validated enzyme-linked immunosorbent assay for the quantitation of immunoglobulin G (IgG) and IgM antibodies against squalene, we demonstrated that antisqualene antibodies are frequently detectable at very low titers in the sera of subjects who were ne

Styles APA, Harvard, Vancouver, ISO, etc.

Chen, Chao-Hung, Yu-Jen Lin, Li-Ting Cheng, Chien-Hung Lin, and Guan-Ming Ke. "Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling." Vaccines 10, no. 5 (2022): 715. http://dx.doi.org/10.3390/vaccines10050715.

Texte intégral

Résumé :

Poloxamer-188 (P188) is a nonionic triblock linear copolymer that can be used as a pharmaceutical excipient because of its amphiphilic nature. This study investigated whether P188 can act as an adjuvant to improve the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) subunit vaccine. BALB/c mice were vaccinated twice with the RBD antigen alone or in combination with P188 or MF59 (a commercial adjuvant for comparison purposes). The resulting humoral and cellular immunity were assessed. Results showed that P188 helped elicit higher neutr

Styles APA, Harvard, Vancouver, ISO, etc.

Lai, Jesse D., Paul C. Moorehead, Kate Sponagle, et al. "Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A." Blood 127, no. 26 (2016): 3439–49. http://dx.doi.org/10.1182/blood-2015-11-679282.

Texte intégral

Résumé :

Key Points Vaccination against influenza, with and without the adjuvant MF59, decreases the risk of inhibitor development in HA mice. Decreased FVIII immunogenicity may be attributed to antigenic competition via T-cell chemotaxis toward the site of vaccination.

Styles APA, Harvard, Vancouver, ISO, etc.

Giusti, Fabiola, Anja Seubert, Rocco Cantisani, et al. "Ultrastructural Visualization of Vaccine Adjuvant Uptake In Vitro and In Vivo." Microscopy and Microanalysis 21, no. 4 (2015): 791–95. http://dx.doi.org/10.1017/s1431927615013744.

Texte intégral

Résumé :

AbstractAdjuvants are substances that enhance adaptive immune responses when formulated in a vaccine. Alum and MF59 are two vaccine adjuvants licensed for human vaccination. Their mode of action has not been completely elucidated. Here we show the first ultrastructural visualization of Alum and MF59 interaction with immune cells in vitro and in vivo. We observed that Alum is engulfed by cells as inclusions of laminae that are detectable within draining lymph nodes. MF59 is instead engulfed by cells in vitro as low-electron-dense lipid-like inclusions that display a vesicle pattern, as confirme

Styles APA, Harvard, Vancouver, ISO, etc.

Ko, Eun-Ju, Young-Tae Lee, Ki-Hye Kim, et al. "Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+T Cells." Journal of Virology 90, no. 15 (2016): 6976–88. http://dx.doi.org/10.1128/jvi.00339-16.

Texte intégral

Résumé :

ABSTRACTCD4+T cells play a central role in orchestrating adaptive immunity. To better understand the roles of CD4+T cells in the effects of adjuvants, we investigated the efficacy of a T-dependent influenza virus split vaccine with MF59 or alum in CD4 knockout (CD4KO) and wild-type (WT) mice. CD4+T cells were required for the induction of IgG antibody responses to the split vaccine and the effects of alum adjuvant. In contrast, MF59 was found to be highly effective in raising isotype-switched IgG antibodies to a T-dependent influenza virus split vaccine in CD4KO mice or CD4-depleted WT mice eq

Styles APA, Harvard, Vancouver, ISO, etc.

Lin, Pin-Hung, and Hung-Chih Yang. "The adjuvant effects of MF59 on antigen-specific regulatory and effector T cells." Journal of Immunology 202, no. 1_Supplement (2019): 196.15. http://dx.doi.org/10.4049/jimmunol.202.supp.196.15.

Texte intégral

Résumé :

Abstract Peptide vaccines are an ideal strategy to induce cross-protective T cell immunity against a broad range of influenza virus strains, but they are subimmunogenic and tend to induce regulatory T (Treg) cells. Our previous study has shown that adjuvanted peptide vaccines can suppress the development of antigen-specific Treg cells. MF59 is the first oil-in-water adjuvant approved for protein-based influenza vaccine, which enhances humoral and Th2 cellular immune responses. However, the role of MF59 in peptide-based vaccines regarding the induction of T cell immunity is unknown. We thus inv

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "MF59 adjuvant prepandemic vaccination"

BORGOGNI, ERICA. "Profiling human cell-mediated immune response to pre-pandemic vaccination." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2009. http://hdl.handle.net/10281/7485.

Texte intégral

Résumé :

Annual influenza A infections affect 5-15% of the population, causing an estimate half million deaths per year worldwide, with the majority of the severe diseases in infants, elderly and immunocompromised individuals. Influenza viruses infect the epithelium of the upper and lower respiratory tracts, typically resulting in an abrupt onset of illness, that usually includes fever, myalgias, upper respiratory tract congestion and pharyngytis. These symptoms persist for approximately one week; pneumonia is a frequent manifestation of more severe infection, while myocarditis, encephalitis and other

Styles APA, Harvard, Vancouver, ISO, etc.

Vono, Maria. "The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination." Doctoral thesis, Università degli studi di Padova, 2014. http://hdl.handle.net/11577/3423482.

Texte intégral

Résumé :

Vaccines are the most effective agents to control infections [1]. In addition to the pathogen antigens, vaccines contain adjuvants that are used to enhance the specific immune responses. Despite their effectiveness and their wide use, the mechanism of action of many adjuvants is poorly characterized [2]. Therefore, adjuvant research is crucial to better understand how they work and to exploit their full potential in vaccinology [3]. Release of endogenous danger signals has been linked to adjuvanticity, however the role of extracellular ATP during vaccination has never been explored. Extracellu

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!